1. Generics Bulletin
  2. >>Policy & Regulation

BGMA Warns No-Deal Brexit Will Harm Depleted UK Stockpile

As European Governments Brace For Possible Second Wave Of COVID-19

 
• By Akriti Seth

While the UK’s drugs stockpile is depleting due to high demand caused by the coronavirus pandemic, a no-deal Brexit in January 2021 may further harm medicines supply during a possible second wave of COVID-19.

Mask_Pills
The UK Government needs to act quickly to rebuild its drug stockpile • Source: Shutterstock

Warning against a non-negotiated exit from the EU in the midst of the COVID-19 pandemic, Warwick Smith, director general of the British Generic Manufacturers Association and the British Biosimilars Association, has cautioned that a “no-deal” Brexit could “potentially disrupt supplies of medicines further at the end of the year.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Generics Bulletin

Cipla Welcomes Abraxane ANDA Approval After Tackling Goa Compliance Issues

 
• By Dean Rudge

Cipla will look to give its US operations a boost later this year by launching only the second Abraxane ANDA product.

Biocon Celebrates Long-Awaited FDA Approval For Bevacizumab Biosimilar

 
• By Urtė Fultinavičiūtė

After having its facility cleared by the FDA earlier in the year, Biocon Biologics finally saw its bevacizumab biosimilar receiving approval in the US.

Emcure’s Subsidiary Tillomed Boosts Portfolio With $20m+ Manx Deal

 
• By Adam Zamecnik

The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.